These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28314411)

  • 1. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4).
    Genung NE; Guckian KM
    Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
    Chaudhary D; Robinson S; Romero DL
    J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
    Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).
    Seganish WM
    Expert Opin Ther Pat; 2016 Aug; 26(8):917-32. PubMed ID: 27310003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Progress in the Molecular Recognition and Therapeutic Importance of Interleukin-1 Receptor-Associated Kinase 4.
    Patra MC; Choi S
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
    Bhide RS; Keon A; Weigelt C; Sack JS; Schmidt RJ; Lin S; Xiao HY; Spergel SH; Kempson J; Pitts WJ; Carman J; Poss MA
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4908-4913. PubMed ID: 28947151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
    McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
    Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of human IRAK1.
    Wang L; Qiao Q; Ferrao R; Shen C; Hatcher JM; Buhrlage SJ; Gray NS; Wu H
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13507-13512. PubMed ID: 29208712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
    McElroy WT
    Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4).
    Wang L; Ferrao R; Li Q; Hatcher JM; Choi HG; Buhrlage SJ; Gray NS; Wu H
    J Biol Chem; 2019 Mar; 294(12):4511-4519. PubMed ID: 30679311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
    Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
    Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel benzenediamine derivate rescued mice from experimental sepsis by attenuating proinflammatory mediators via IRAK4.
    Dou H; Song Y; Liu X; Yang L; Jiang N; Chen D; Li E; Tan R; Hou Y
    Am J Respir Cell Mol Biol; 2014 Aug; 51(2):191-200. PubMed ID: 24588661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.
    Hanisak J; Seganish WM; McElroy WT; Tang H; Zhang R; Tsui HC; Fischmann T; Tulshian D; Tata J; Sondey C; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4250-5. PubMed ID: 27476420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.
    Chen L; Luo R; Ma L; Xu Y; Cao J; Jiang Z; Chen S; Huang X; Zhang M; Zheng L; Zhang Y; Yin L; Yu J; Zheng X; Zheng L; Huang P; Liang G
    J Med Chem; 2024 May; 67(10):8060-8076. PubMed ID: 38722184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.
    Bryan MC; Drobnick J; Gobbi A; Kolesnikov A; Chen Y; Rajapaksa N; Ndubaku C; Feng J; Chang W; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Huang Z; Sujatha-Bhaskar S; Brightbill H; DiPasquale A; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR
    J Med Chem; 2019 Jul; 62(13):6223-6240. PubMed ID: 31082230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
    Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L
    Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing and Validating Cellular Functional Target Engagement Assay for Selective IRAK4 Inhibitor Discovery.
    Chen Y; Sun D; Yang R; Lim J; Sondey C; Presland J; Rakhilina L; Addona G; Kariv I; Chen H
    SLAS Discov; 2021 Sep; 26(8):1040-1054. PubMed ID: 34130529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.
    Zhang J; Fu L; Shen B; Liu Y; Wang W; Cai X; Kong L; Yan Y; Meng R; Zhang Z; Chen YP; Liu Q; Wan ZK; Zhou T; Wang X; Gavine P; Del Rosario A; Ahn K; Philippar U; Attar R; Yang J; Xu Y; Edwards JP; Dai X
    Cell Chem Biol; 2020 Dec; 27(12):1500-1509.e13. PubMed ID: 32888499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
    Lee KL; Ambler CM; Anderson DR; Boscoe BP; Bree AG; Brodfuehrer JI; Chang JS; Choi C; Chung S; Curran KJ; Day JE; Dehnhardt CM; Dower K; Drozda SE; Frisbie RK; Gavrin LK; Goldberg JA; Han S; Hegen M; Hepworth D; Hope HR; Kamtekar S; Kilty IC; Lee A; Lin LL; Lovering FE; Lowe MD; Mathias JP; Morgan HM; Murphy EA; Papaioannou N; Patny A; Pierce BS; Rao VR; Saiah E; Samardjiev IJ; Samas BM; Shen MWH; Shin JH; Soutter HH; Strohbach JW; Symanowicz PT; Thomason JR; Trzupek JD; Vargas R; Vincent F; Yan J; Zapf CW; Wright SW
    J Med Chem; 2017 Jul; 60(13):5521-5542. PubMed ID: 28498658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.